A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors**
[4];
more »
- Texas A & M Univ., College Station, TX (United States)
- Texas A & M Univ. at Galveston, TX (United States). University of Texas Medical Branch
- Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
- Univ. of North Texas, Fort Worth, TX (United States). UNT Health Science Center
The COVID-19 pathogen, SARS-CoV-2, requires its main protease (SC2MPro ) to digest two of its translated long polypeptides to form a number of mature proteins that are essential for viral replication and pathogenesis. Inhibition of this vital proteolytic process is effective in preventing the virus from replicating in infected cells and therefore provides a potential COVID-19 treatment option. Guided by previous medicinal chemistry studies about SARS-CoV-1 main protease (SC1MPro ), we have designed and synthesized a series of SC2MPro inhibitors that contain β-(S-2-oxopyrrolidin-3-yl)-alaninal (Opal) for the formation of a reversible covalent bond with the SC2MPro active-site cysteine C145. All inhibitors display high potency with Ki values at or below 100 nM. The most potent compound, MPI3, has as a Ki value of 8.3 nM. Crystallographic analyses of SC2MPro bound to seven inhibitors indicated both formation of a covalent bond with C145 and structural rearrangement from the apoenzyme to accommodate the inhibitors. Virus inhibition assays revealed that several inhibitors have high potency in inhibiting the SARS-CoV-2-induced cytopathogenic effect in both Vero E6 and A549/ACE2 cells. Two inhibitors, MPI5 and MPI8, completely prevented the SARS-CoV-2-induced cytopathogenic effect in Vero E6 cells at 2.5-5 μM and A549/ACE2 cells at 0.16-0.31 μM. Their virus inhibition potency is much higher than that of some existing molecules that are under preclinical and clinical investigations for the treatment of COVID-19. Our study indicates that there is a large chemical space that needs to be explored for the development of SC2MPro inhibitors with ultra-high antiviral potency.
- Research Organization:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC), Basic Energy Sciences (BES). Scientific User Facilities Division
- Grant/Contract Number:
- AC02-05CH11231; P30 GM124169-01; R01GM127575; R01GM121584; R01AI145287
- OSTI ID:
- 1837373
- Journal Information:
- ChemMedChem, Vol. 16, Issue 6; ISSN 1860-7179
- Publisher:
- ChemPubSoc EuropeCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice